A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, parallel group, multicentre clinical study to evaluate
the efficacy, safety, pharmacokinetics and immunogenicity of SB4 compared to Enbrel in
subjects with moderate to severe Rheumatoid Arthritis (RA) despite Methotrexate (MTX)
therapy. In some countries, after 52 weeks of treatment with either SB4 or Enbrel, subjects
will be enrolled into an open label extension period. Subjects will receive SB4 for an
additional 48 weeks.